1.Novel Bronchoscopy Method for Molecular Profiling of Lung Cancer: Targeted Washing Technique
Mi-Hyun KIM ; Hayoung SEONG ; Hyojin JANG ; Saerom KIM ; Wanho YOO ; Soo Han KIM ; Jeongha MOK ; Kwangha LEE ; Ki Uk KIM ; Min Ki LEE ; Jung Seop EOM
Cancer Research and Treatment 2026;58(1):107-114
Purpose:
There have been efforts to find alternative samples other than standard samples of tissue or plasma for mutational analyses for lung cancer patients. However, no other sample or technique has replaced the mutational analyses using standard samples. In this prospective study, we assessed a novel bronchoscopy method, named as targeted washing technique, for detecting the epidermal growth factor receptor (EGFR) mutation.
Materials and Methods:
A 3.0-mm ultrathin bronchoscope was precisely navigated to the target lung lesion with the assistance of virtual bronchoscopic navigation and fluoroscopy. Once the bronchoscope is placed in front of target lung lesion, 0.9% normal saline was instilled for targeted washing. EGFR testing using targeted washing fluid (TWF) was compared to standard methods using plasma or tumor tissue.
Results:
In 41 TWF samples, the T790M mutation was detected in tissue, plasma, and TWF samples at rates of 22.0%, 9.8%, and 29.3%, respectively. The overall EGFR T790M detection rate using tissue, plasma, or TWF samples was 36.6%, with TWF samples increasing the T790M mutation detection rate by up to 10%. The accuracy of T790M mutation detection using TWF sample was 82.9% compared with standard samples. Four patients were found to have the EGFR T790M mutation solely through EGFR testing using TWF, which repeated rebiopsies using either plasma or tissue finally confirmed to have the T790M mutation.
Conclusion
We demonstrated the clinical potential of targeted washing technique for molecular testing, which can be a good option to overcome spatial heterogeneity, low sensitivity of plasma sample or technical limitations in collecting tumor tissues.
2.Real-World Experience of Weekly Carfilzomib in Combination with Cyclophosphamide and Dexamethasone in Multiple Myeloma Relapsed/Refractory to Bortezomib and Lenalidomide
Cheongin YANG ; Changgon KIM ; Kunye KWAK ; Ka-Won KANG ; Yong PARK ; Byung Soo KIM ; Seong Hyun JEONG ; Joon Seong PARK ; Yoon Seok CHOI
Cancer Research and Treatment 2026;58(1):320-328
Purpose:
This retrospective study evaluated the efficacy and safety of a weekly carfilzomib, cyclophosphamide, and dexamethasone (KCd) regimen in patients with relapsed or refractory multiple myeloma (RRMM) who had been previously treated with both bortezomib- and lenalidomide-containing regimens.
Materials and Methods:
We conducted a retrospective analysis of 33 patients with RRMM who received the KCd regimen between March 2020 and February 2024. All patients had prior exposure to both bortezomib and lenalidomide, and the majority (93.9%) were refractory to lenalidomide. Carfilzomib was administered once weekly at 70 mg/m2 (after a step-up dose), along with oral cyclophosphamide and dexamethasone. Treatment response was assessed according to the International Myeloma Working Group criteria, and survival outcomes were analyzed.
Results:
The overall response rate was 66.7%, including a complete response or better in 15.1% of patients and a very good partial response or better in 42.4%. With a median follow-up of 31.7 months, the median progression-free survival was 13.5 months (95% confidence interval, 11.47 to 15.53), while the median overall survival was not reached. The most common grade ≥ 3 adverse event was neutropenia (15.2%). Non-hematologic grade ≥ 3 toxicities were infrequent and manageable.
Conclusion
The weekly KCd regimen demonstrated encouraging efficacy and tolerability in a heavily pretreated RRMM population. These findings support its use as a feasible treatment option, particularly in patients refractory to lenalidomide.
3.Attitude Toward Infection Prevention and Utilization of Local Mental Health Services During the COVID-19 Pandemic in Patient With Schizophrenia
Jun Yeong HEO ; Hyun Soo KIM ; Seong Hwan KIM
Journal of the Korean Society of Biological Therapies in Psychiatry 2026;32(1):52-65
Objectives:
This study aims to investigate the challenges faced by individuals with schizophrenia in adhering to COVID-19 prevention guidelines and the difficulties they experienced due to social distancing measures.
Methods:
The study focused on 286 registered members with schizophrenia who were utilizing mental health welfare center services in the Busan area. The general control group consisted of individuals aged 19 and older in Busan. A survey was used to examine changes in daily life due to COVID-19 and perceptions of preventive measures. The survey also investigated the difficulties in daily life and the services needed by individuals with schizophrenia after the onset of COVID-19.To compare the two groups, independent sample t-tests were used for continuous variables, and chi-square tests were conducted for categorical variables.
Results:
Compared to the general population, individuals with schizophrenia reported lower levels of anxiety about contracting COVID-19 and experiencing fatal outcomes. They also indicated that they were less likely to engage in new activities or experience conflicts with those around them. Additionally, they rated the necessity of COVID-19 preventive guidelines lower and reported experiencing less stress from adhering to these guidelines. However, individuals with schizophrenia expressed significant discomfort due to the reduction in face-to-face counseling as a result of the suspension of mental health welfare center services. They also reported difficulties with attending outpatient appointments and maintaining regular meals, among other challenges.
Conclusions
In this study, it was observed that individuals with schizophrenia tended to underestimate the risk and severity of COVID-19 infection and found it challenging to recognize the necessity of preventive measures. Additionally, they appeared to experience greater difficulties in managing their daily lives independently.
4.Optimal use and cycling strategies of Janus kinase inhibitors in ulcerative colitis: current evidence and clinical implications from the KASID Guidelines Task Force Team
Seung Min HONG ; Dong Hyun KIM ; June Hwa BAE ; Seung Yong SHIN ; Eun Mi SONG ; Ji Eun KIM ; Young Joo YANG ; Jiyoung YOON ; Sang-Bum KANG ; Eun Soo KIM ; Seong-Eun KIM ; Seong-Jung KIM ; Jun LEE ; Soo-Young NA ; Soo Jung PARK ; Sang Hyoung PARK ; Miyoung CHOI ; Myung Ha KIM ; Won MOON ; Sung-Ae JUNG ;
Intestinal Research 2026;24(1):27-37
Janus kinase (JAK) inhibitors are an important treatment option for ulcerative colitis, providing rapid onset of action, oral administration, and efficacy even after biologic failure. The 3 approved agents—tofacitinib, filgotinib, and upadacitinib—differ in JAK isoform selectivity, leading to clinically meaningful differences in efficacy and safety. Evidence from network meta-analyses, clinical trials, and real-world studies consistently shows that upadacitinib provides the highest efficacy for induction and maintenance of remission, whereas filgotinib demonstrates the most favorable safety profile. The strong efficacy of upadacitinib and tofacitinib is particularly relevant in patients with severe disease, including acute severe ulcerative colitis, and upadacitinib maintains high efficacy regardless of prior advanced therapy exposure. JAK inhibitors also benefit extraintestinal manifestations. Although risks such as herpes zoster, serious infection, thromboembolism, and major cardiovascular events differ among agents, long-term data suggest generally acceptable safety when used appropriately. Intraclass JAK-to-JAK cycling is feasible, with about half of patients achieving steroid-free clinical remission in retrospective cohorts. Based on mechanistic, clinical, and real-world evidence, filgotinib may be a first-line option for patients with lower disease activity or when safety is a priority, whereas upadacitinib or tofacitinib may be preferred in higher disease activity. Strategically selecting agents may improve durability and outcomes.
5.PNPLA3 I148M is unrelated to HCC occurrence but associates with poorer tumor differentiation in Korean MASLD: a prospective cohort of 562 patients
Jaejun LEE ; Dong Yeop LEE ; Jung Hoon CHA ; Hee Sun CHO ; Keungmo YANG ; Hyun YANG ; Mi Young BYUN ; Seok Keun CHO ; Seong Wook YANG ; Si Hyun BAE ; Pil Soo SUNG
Journal of Liver Cancer 2026;26(1):147-156
Background:
s/Aims: The patatin-like phospholipase domain-containing protein 3 (PNPLA3) I148M variant has been implicated in metabolic dysfunction-associated steatotic liver disease (MASLD), but its role in hepatocellular carcinoma (HCC) development is unclear. This study examines the association between the PNPLA3 I148M variant and HCC occurrence.
Methods:
A total of 562 MASLD patients, with and without HCC, were prospectively and consecutively enrolled at two universityaffiliated hospital between June 2024 and June 2025. Genomic DNA was extracted from buccal swabs or liver biopsy samples, and single nucleotide polymorphism genotyping was performed to determine the rs738409 genotype at codon 148 of PNPLA3. The histological grade of HCC was assessed using the Edmondson-Steiner (ES) grading system in patients who underwent core-needle liver biopsy.
Results:
Among 474 non-HCC patients, the GG genotype was found in 39.9%, GC in 37.1%, and CC in 23.0%. In 88 HCC patients, these frequencies were 45.5%, 36.4%, and 18.2%, respectively. No significant differences in GG genotype distribution were observed between HCC and non-HCC groups (P=0.509), nor in subgroups by sex, age, obesity status, cirrhosis status, fibrosis-4 index, or liver stiffness measurement. However, among HCC patients with histological grading, the GG genotype was significantly associated with higher ES grades (P=0.0076).
Conclusions
The PNPLA3 I148M GG genotype was not significantly associated with increased HCC occurrence in Korean MASLD patients within the present cohort. Although the GG genotype is known to play a role in development and progression of MASLD, further studies are warranted to clarify its contribution to tumor initiation and dedifferentiation.
6.Cervical Spinal Melanocytoma: A Case Report and Literature Review
Chan Joo PARK ; Soo Hyun LEE ; Do Heum YOON ; Seong Bae AN ; Inbo HAN ; Seung Hun SHEEN ; Sun-Yoon CHUNG ; Jinhyung HEO ; Hye Jeong CHOI ; Seil SOHN
The Nerve 2026;12(1):56-60
Spinal melanocytoma (SMC) is a rare, slow-growing tumor arising from melanocytes in the spinal cord. We report a patient with a cervical intra- and extradural spinal tumor causing progressive weakness and numbness. On magnetic resonance imaging (MRI), the lesion showed intense homogeneous enhancement, similar to that seen in common neurogenic spinal tumors. After complete resection, pathological examination confirmed melanocytoma. A review of previously reported cases identified 26 reports of this tumor in the cervical spine, most of which were treated with complete surgical resection. Gross total resection is the preferred treatment, although radiation therapy may be considered when residual tumor remains. We report a 25-year-old male patient who presented with progressive weakness and numbness in both the upper and lower extremities for 3 months. MRI showed homogeneous enhancement. The mass compressed the spinal cord at C6–7 and extended through the neural foramen. Based on the MRI findings, spinal schwannoma was suspected preoperatively. Surgical resection was performed with laminectomy, durotomy, and right facetectomy. A dark-colored mass with well-demarcated margins was exposed and removed. Postoperative MRI confirmed complete removal of the mass. The patient recovered well, and his preoperative myelopathic symptoms gradually improved. SMC is a rare benign tumor that may be mistaken for schwannoma. The treatment of choice is gross total resection.
7.Systemic Gaps in Heart Failure Care and the Need for Specialized Management: A Nationwide Survey of Korean Cardiologists
SungA BAE ; Soo-Yong LEE ; So-Ree KIM ; Minjae YOON ; Kang Un CHOI ; Junho HYUN ; Kyung-Hee KIM ; Suk Min SEO ; Byung-Su YOO ; Seong-Mi PARK ;
International Journal of Heart Failure 2026;8(1):95-100
8.Corrigendum: Correction of Funding in the Article “List of occupational diseases among farmers in Korea: a literature review”
Hansoo SONG ; Seok-Ju YOO ; Won-Ju PARK ; Seunghyeon CHO ; Ki Soo PARK ; Joo Hyun SUNG ; Sang Jin PARK ; Seong-yong YOON ; Kyeongsoo KIM ; Dong-phil CHOI ; Hye-min KIM ; Bounggyun JU ; Kanwoo YOUN
Annals of Occupational and Environmental Medicine 2025;37(1):e16-
9.List of occupational diseases among farmers in Korea: a literature review
Hansoo SONG ; Seok-Ju YOO ; Won-Ju PARK ; Seunghyeon CHO ; Ki Soo PARK ; Joo Hyun SUNG ; Sang Jin PARK ; Seong-yong YOON ; Kyeongsoo KIM ; Dong-phil CHOI ; Hye-min KIM ; Bounggyun JU ; Kanwoo YOUN
Annals of Occupational and Environmental Medicine 2025;37(1):e2-
A comprehensive list of occupational diseases among farmers is crucial for both compensation and prevention efforts. In Korea, most farmers are self-employed, and some occupational diseases are compensated through farmer safety insurance. However, it is not harmonized with industrial accident compensation insurance and does not adequately reflect the true burden of occupational diseases among farmers. To address this gap, the authors compiled a list of occupational diseases tailored to Korean farmers by reviewing the International Labor Organization’s list of occupational diseases, the Korean Industrial Accident Compensation Insurance List, the occupational disease lists of other countries, and relevant literature on farmers’ work-related diseases.
10.Force and moment analysis of clear aligners: Impact of material properties and design on premolar rotation
Dong-Woo KIM ; Hyun-Jun LEE ; Ki Beom KIM ; Sung-Hun KIM ; Seong-Sik KIM ; Soo-Byung PARK ; Youn-Kyung CHOI ; Yong-Il KIM
The Korean Journal of Orthodontics 2025;55(3):212-223
Objective:
To quantitatively analyze and compare the forces and moments generated by thermoformed polyethylene terephthalate glycol (PETG) and direct-printed TC-85 clear aligners (CAs), with various margin designs, during premolar rotation.
Methods:
In total, 132 CAs were fabricated and divided into four groups (n = 33 per group). Group C consisted of thermoformed PETG aligners with a 2 mm gingival margin. Group E comprised direct-printed TC-85 aligners with equi-gingival margin, whereas Group G utilized direct-printed TC-85 aligners with 2 mm gingival margins.Finally, Group T featured direct-printed TC-85 aligners with an additional 1 mm thickness at the mesial embrasure. The forces and moments were measured using a 6-axis force/moment transducer at 2°, 3°, and 4° of rotation. All measurements were conducted at 37°C to simulate intraoral conditions. Forces were measured in the buccolingual, anteroposterior, and vertical directions, while moments were measured in the mesiodistal, buccolingual, and rotational planes.
Results:
The PETG aligners (Group C) showed significantly increased buccal and posterior force across the rotation angles (P < 0.05), whereas the intrusive force remained consistent. In contrast, the TC-85 aligners maintained consistent forces across all rotation angles.Direct-printed aligners demonstrated significantly lower intrusive forces than PETG aligners (P < 0.001). Group T exhibited reduced unwanted forces while maintaining effective rotational moments. Furthermore, all direct-printed aligners showed more predictable force delivery patterns than thermoformed aligners.
Conclusions
Direct-printed TC-85 aligners demonstrated superior force consistency and reduced unwanted side effects compared with traditional PETG aligners. Although marginal design modifications did not significantly improve rotational efficiency, they effectively reduced unwanted intrusive forces.

Result Analysis
Print
Save
E-mail